HNN3.0
Register
Register
Register

Project cooperationUpdated on 5 January 2026

Novel "Innate" Approaches for Vaccines in Low- and Middle-Income Countries

Associate Professor (Italian National Research Council) at Consiglio Nazionale delle Ricerche

Palermo, Italy

About

This project will try to offer a different point-of-view from the pathogen-specific vaccination to a broad-spectrum innate immune preparedness. Novel "vaccine" formulations designed to potently and safely modulate the innate immune system can establish a "quick protectio" of against new viruses. This "trained" or "broadly reactive" immunity could act as a universal first line of defense, controlling early viral replication and reducing severe disease from novel pathogens, independent of a specific vaccine.

The core strategy is to enhance innate immune pathways that are common to many viral families. This approach seeks to provide immediate, cross-protective benefits, buying crucial time for the development and global distribution of specific vaccines.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

Organisation

Consiglio Nazionale delle Ricerche

R&D Institution

Rome, Italy

Similar opportunities

  • Project cooperation

    Modified Vaccinia Ankara (MVA) platform for strong T-cell immune responses

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

    Angelo Raggioli

    Head of Technology Development at ReiThera srl

    Rome, Italy

  • Project cooperation

    Adenoviral vaccine platform

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential

    Angelo Raggioli

    Head of Technology Development at ReiThera srl

    Rome, Italy

  • Project cooperation

    Rapid immune response novel platform, diagnostics prognostics

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Michelle Kilcoyne

    Lecturer in Glycosciences at University of Galway

    Galway, Ireland